Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2018-10-09, Stock:JNJ, The news for the past five days is as follows:
2018-10-02: NEWS1: Health Care Sector Update for 10/02/2018: VSTM,MMSI,JNJ,ICPT.NEWS2: Health Care Sector Update for 10/02/2018: VSTM,MMSI,JNJ,ICPT.NEWS3: Health Care Sector Update for 10/02/2018: MMSI,JNJ,LLY.NEWS4: Health Care Sector Update for 10/02/2018: MMSI,JNJ,LLY.NEWS5: Tracking the traders' most memorable calls in Q3.NEWS6: [$$] Johnson & Johnson Closes Sale of LifeScan to Platinum Equity.NEWS7: Are You Looking for a High-Growth Dividend Stock? Johnson & Johnson (JNJ) Could Be a Great Choice.NEWS8: Are You Looking for a High-Growth Dividend Stock? Johnson & Johnson (JNJ) Could Be a Great Choice.NEWS9: Are You Looking for a High-Growth Dividend Stock? Johnson & Johnson (JNJ) Could Be a Great Choice.NEWS10: Health Care Sector Update for 10/02/2018: JNJ,LLY.NEWS11: Health Care Sector Update for 10/02/2018: JNJ,LLY.NEWS12: A Look at GlaxoSmithKline’s Consumer Healthcare Business.NEWS13: Platinum Equity Completes $2.1 Billion Acquisition of LifeScan From Johnson & Johnson.NEWS14: Johnson & Johnson Completes Divestiture of LifeScan to Platinum Equity.NEWS15: Johnson & Johnson Closes Sale Of LifeScan Business To Platinum Equity.NEWS16: Johnson & Johnson Closes Sale Of LifeScan Business To Platinum Equity.
2018-10-03: NEWS1: Merck CEO sees a disintermediation in pharma like the cable industry.NEWS2: Platinum Equity completes $2B purchase of J&J’s LifeScan.NEWS3: Mergers and Acquisitions in the Pharmaceuticals Sector in Q3 2018.NEWS4: Here's Why J&J (JNJ) is a Good Bet in a Troubled Market.NEWS5: Here's Why J&J (JNJ) is a Good Bet in a Troubled Market.NEWS6: Novartis, Boston Pharma Ink Deal for 3 Anti-Infective Drugs.NEWS7: Novartis, Boston Pharma Ink Deal for 3 Anti-Infective Drugs.NEWS8: Merck & Other Pharma Players Await FDA Decisions in October.NEWS9: Merck & Other Pharma Players Await FDA Decisions in October.NEWS10: Here&apos;s Why J&J (JNJ) is a Good Bet in a Troubled Market.NEWS11: MARKETS: Dow hits another record with Intel, Apple, Caterpillar leading—even small caps are on board.NEWS12: A Look at Elanco, Eli Lilly’s Animal Health Business.NEWS13: Novartis, Boston Pharma Ink Deal for 3 Anti-Infective Drugs.NEWS14: Merck & Other Pharma Players Await FDA Decisions in October.NEWS15: Health Care Sector Update for 10/03/2018: JNJ, PFE, AMGN, MRK, ABT, ELGX, NVCN, KALA.NEWS16: Health Care Sector Update for 10/03/2018: JNJ, PFE, AMGN, MRK, ABT, ELGX, NVCN, KALA.NEWS17: Bristol-Myers Squibb Company (BMY) Ex-Dividend Date Scheduled for October 04, 2018.NEWS18: Bristol-Myers Squibb Company (BMY) Ex-Dividend Date Scheduled for October 04, 2018.NEWS19: Dow Jones Futures Rise On Italy: Upwork IPO Set To Debut; News On Nike, Microsoft, J&J.NEWS20: Will This IRS Spinoff Rule Help Pharma and Big Tech?.NEWS21: Will This IRS Spinoff Rule Help Pharma and Big Tech?.NEWS22: Will This IRS Spinoff Rule Help Pharma and Big Tech?.
2018-10-04: NEWS1: MARKETS: Don't freak out about today's selloff, but retail is still in trouble.NEWS2: Top Performing ETFs of the Third Quarter.NEWS3: Top Performing ETFs of the Third Quarter.NEWS4: J&J, Arrowhead in gene-silencing drug deal worth up to $3.7 billion.NEWS5: 7 Healthcare Stocks to Buy Right Now.NEWS6: Seattle Genetics: Impact of the Cascadian Acquisition.NEWS7: Stocks - Apple, Amazon Fall in Pre-market; Barnes & Noble Surges.NEWS8: J&J's Phase III Data Shows Switch to its HIV Drug Beneficial.NEWS9: J&J's Phase III Data Shows Switch to its HIV Drug Beneficial.NEWS10: Health-Care Stocks’ High Valuations May Not Be a Problem.NEWS11: Arrowhead Announces $3.7B License Agreement With Janssen For Gene-Silencing Drug.NEWS12: J&J&apos;s Phase III Data Shows Switch to its HIV Drug Beneficial.NEWS13: J&J, Arrowhead in gene-silencing drug deal worth up to $3.7 billion.NEWS14: The Daily Biotech Pulse: AtriCure's Guidance, Guardant Health And Kodiak To Debut.NEWS15: UPDATE: Arrowhead Pharma stock surges 19% on news of $3.7 billion license agreement with Janssen.NEWS16: Eli Lilly’s Stock Performance and Estimates for Q3 2018.NEWS17: Arrowhead Enters $3.7 Bln License And Collaboration Deals With Janssen.NEWS18: Arrowhead Enters $3.7 Bln License And Collaboration Deals With Janssen.NEWS19: Moody's: Biosimilars a growing challenge biotech drugs, with European market developing more quickly than the US.
2018-10-05: NEWS1: Johnson & Johnson Stock in the Week Ended October 5.NEWS2: Cara Therapeutics: Recommendations and Market Capitalization.NEWS3: J&J Inks Deal With Arrowhead for Promising Liver Candidate.NEWS4: J&J Inks Deal With Arrowhead for Promising Liver Candidate.NEWS5: 8 Stocks to Buy That Will Never Go Out of Style.NEWS6: Pharma Stock Roundup: PFE to Get New CEO, LLY Presents Impressive Diabetes Data.NEWS7: Pharma Stock Roundup: PFE to Get New CEO, LLY Presents Impressive Diabetes Data.NEWS8: J&J Inks Deal With Arrowhead for Promising Liver Candidate.NEWS9: MARKETS: Nike, McDonald's leading the Dow higher, as big banks get a bump.NEWS10: Pharma Stock Roundup: PFE to Get New CEO, LLY Presents Impressive Diabetes Data.NEWS11: Health Care Sector Update for 10/05/2018: JNJ, PFE, ABT, MRK, AMGN, HSGX, KMPH.NEWS12: Health Care Sector Update for 10/05/2018: JNJ, PFE, ABT, MRK, AMGN, HSGX, KMPH.NEWS13: What Seattle Genetics’ Valuation Trend Indicates.NEWS14: Bull of the Day: Roche (RHHBY).NEWS15: Bull of the Day: Roche (RHHBY).NEWS16: 7 Healthcare Stocks to Buy Right Now.NEWS17: 7 Healthcare Stocks to Buy Right Now.
2018-10-08: NEWS1: Johnson & Johnson Offers an Attractive Investment Proposition.NEWS2: Notable Monday Option Activity: AKCA, ACN, JNJ.NEWS3: Notable Monday Option Activity: AKCA, ACN, JNJ.NEWS4: Are These Beaten-Down Clinical-Stage Biotech Stocks Buys?.NEWS5: Are These Beaten-Down Clinical-Stage Biotech Stocks Buys?.NEWS6: Broker Darlings of the Dow: Pfizer Ranks As a Top 15 Analyst Pick.NEWS7: Broker Darlings of the Dow: Pfizer Ranks As a Top 15 Analyst Pick.NEWS8: Johnson & Johnson Vision Launches Worldwide Campaign to #SpotlightSight in Honor of World Sight Day.NEWS9: Are These Beaten-Down Clinical-Stage Biotech Stocks Buys?.NEWS10: Geron Stock: Buy, Sell, or Hold?.NEWS11: Geron Stock: Buy, Sell, or Hold?.NEWS12: JNJ’s $3.7 Billion Deal for Hepatitis B Gene Silencing Drug.NEWS13: Geron Stock: Buy, Sell, or Hold?.NEWS14: Is Arrowhead Pharmaceuticals, Inc. a Buy on the Dip?.NEWS15: Is Arrowhead Pharmaceuticals, Inc. a Buy on the Dip?.NEWS16: How Is Arrowhead Pharmaceuticals Stock Positioned?.NEWS17: See what the IHS Markit Score report has to say about Johnson & Johnson..NEWS18: Is Arrowhead Pharmaceuticals, Inc. a Buy on the Dip?.NEWS19: 8 Stocks to Buy That Will Never Go Out of Style.NEWS20: 8 Stocks to Buy That Will Never Go Out of Style.

Answer: Decrease